When is Adjuvant Therapy Indicated for Cutaneous Melanoma?
Adjuvant systemic therapy should be offered to all patients with resected stage IIB-IIC and stage III-IV cutaneous melanoma, with specific regimens determined by stage and BRAF mutation status. 1
Stage-Specific Indications
Stage IIB-IIC (High-Risk Stage II)
- Offer adjuvant pembrolizumab or nivolumab for 52 weeks 1
- These patients have no regional lymph node involvement but carry recurrence risk comparable to stage III disease
- Pembrolizumab showed 18-month RFS of 86% vs 77% with placebo (HR 0.61) 1
- Nivolumab demonstrated 12-month EFS of 89% vs 79% with placebo (HR 0.42) 1
Critical caveat: Stage IIA patients were not included in pivotal trials and should not routinely receive adjuvant therapy given their lower risk profile.
Stage IIIA Disease
- Exercise caution with adjuvant therapy in stage IIIA, particularly with sentinel node metastases <1mm 1
- These patients have relatively better prognosis and were excluded from major trials
- Recent data suggests anti-PD1 therapy did not significantly improve outcomes compared to observation in stage IIIA 2
- Treatment should be individualized based on additional high-risk features (higher Breslow thickness, elevated mitotic rate)
Stage IIIB-IV (Resectable Disease)
For BRAF wild-type:
- Offer nivolumab OR pembrolizumab for 52 weeks (no particular order of preference) 1
- Both agents show strong efficacy with similar toxicity profiles
For BRAF V600E/K mutant:
- Offer nivolumab OR pembrolizumab OR dabrafenib plus trametinib for 52 weeks 1
- Choice between immunotherapy vs targeted therapy remains controversial
- Consider targeted therapy (dabrafenib/trametinib) for patients requiring rapid disease control or with contraindications to immunotherapy
- Immunotherapy may offer more durable responses but with immune-related toxicities
Neoadjuvant Approach for Resectable Stage IIIB-IV
For clinically positive nodes or satellite/in-transit metastases, neoadjuvant pembrolizumab is now preferred over upfront surgery 3, 1:
- Give 3 cycles of pembrolizumab 200mg every 3 weeks
- Followed by surgical resection
- Then complete adjuvant pembrolizumab for 15 additional cycles
This approach showed 72% event-free survival at 2 years vs 49% with adjuvant-only treatment 3. The neoadjuvant strategy is generally preferred over the previous standard of therapeutic lymph node dissection followed by adjuvant therapy 3.
Regimens NOT Recommended
Do not routinely use:
- High-dose interferon (inferior efficacy, significant toxicity) 1
- Ipilimumab monotherapy (inferior to anti-PD1 agents) 1
- Nivolumab plus ipilimumab combination (CheckMate 915 showed no RFS or OS benefit over nivolumab alone, with 32.6% vs 12.8% grade 3-4 toxicity) 1
Key Toxicity Considerations
- Grade ≥3 treatment-related adverse events: 10-16% with anti-PD1 monotherapy 3, 1
- Grade ≥3 events: 17.5% with dabrafenib/trametinib 2
- Discontinuation rates: 13.3% for anti-PD1, 21.2% for targeted therapy 2
- Unresolved toxicity at follow-up: 26.9% with anti-PD1 2
Common Pitfalls to Avoid
- Do not extrapolate stage III data to stage IIIA with minimal nodal disease - these patients may not benefit and face unnecessary toxicity risk
- Do not assume all BRAF-mutant patients need targeted therapy - immunotherapy remains a valid first-line option
- Do not delay neoadjuvant therapy in resectable stage IIIB-IV - this approach is now preferred over upfront surgery
- Do not use combination immunotherapy (nivolumab/ipilimumab) in the adjuvant setting - no benefit over monotherapy with substantially higher toxicity